Answers are grounded in this paper and cite their sources.
Background: Although early-stage non-small cell lung cancer (NSCLC) is associated with a more favorable prognosis than advanced-stage disease, the 5-year survival rate declines to roughly 50% when tumors exhibit significant growth, local invasion, or regional lymph node involvement. Liquid biopsy utilizing circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment offers a promising noninvasive tool for prognostication and early relapse detection;nevertheless, robust clinical validation in early-stage NSCLCremains scarce.Methods:This retrospective study comprised309 serial plasma samples from 74 patients with early-stage NSCLC, predominantly stage Iand adenocarcinoma. Dynamic ctDNA/MRD monitoring was conducted to evaluate the predict recurrence, risk stratification and outcome. In addition, mutational profiles and cfDNA fragmentation features were also assessed.Results:MRD positivity was associated with significantly reduced disease-free survival (DFS). For stage I patients, landmark MRD positivity was associated with an increased risk of recurrence (HR, 8.03; 95% CI, 1.79–36.11; p = 0.007), while longitudinal MRD positivity showed similarly strong prognostic value (HR, 9.86; 95% CI, 1.96–49.54; p = 0.005). Longitudinal monitoring after surgery can further increase the prognostic value of ctDNA testing and enables detection of disease recurrence earlier thanlandmark MRD analysis. Longitudinal MRD monitoring achieved a negative predictive value of 100%. MRD detection preceded conventional radiologic recurrence by a median of 18.05 months. Higher postoperative ctDNA concentration was associated with inferior DFS, and integration of MRD status with ctDNA concentration further improved risk stratification. Time-dependent Cox modeling demonstrated that ctDNA-negative status was dynamically associated with favorable relapse-free probability over time. Fragmentation analysis showed enrichment of mutation-associated reads within 150–200 bp fragments, with ~170 bp mutant fragments being particularly prominent in MRD-positive and recurrence-prone patients.Conclusions:Postoperative ctDNA/MRD analysis is effective in early detection of MRD and relapse risk stratification of NSCLC, supporting the potential role of dynamic ctDNA-guided surveillance in personalized postoperative management of early-stage NSCLC.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: